Natera Reports Third Quarter 2026 Financial Results
Natera (NTRA) reported Q3 2026 revenues of $794.0M, up 34.1% YoY, with 1,093,100 tests processed. Gross margin was 64.7%, and oncology tests grew 60.9%. The company raised 2026 revenue guidance to $3.005B-$3.035B. Cash increased by $5.7M QoQ, and net loss narrowed to $59.9M.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise are likely to move NTRA higher in after‑hours trading and set a bullish tone for the upcoming quarter.
Market read
First‑time disclosure of Q3 results and guidance lift makes this a high‑impact earnings event for the stock.
What to watch
Higher operating expenses and a modest cash increase could temper enthusiasm.
Background
The press release provides detailed Q3 financials, test volumes, margin trends, and updated 2026 revenue guidance.
Ticker impact
Natera reported Q3 2026 results with revenue up 34% YoY and raised full-year revenue guidance by $140 million.
likely upward pressure as investors price in better-than-expected results and raised guidance
Revenue and test volume growth beat expectations; guidance lift signals improved market demand, which typically drives the stock higher in the short term.
Market effects
Boosts outlook for the broader genetic‑testing and precision‑medicine sector.
Positive for US biotech and healthcare stocks.
Limited to investors tracking biotech earnings; no global macro effect.
Counterpoint
If the market has already priced in the guidance lift, the stock may face a short‑term pullback.
Key entities
- companyNatera, Inc.
Provider of cell‑free DNA and precision‑medicine diagnostics.
